Risperidone in the treatment of patients with Alzheimer's disease with negative symptoms

International Psychogeriatrics

Volumn 12, Issue 4, 2000, Pages 527-536

  Negrón, Arnaldo E ^a,b   Reichman, William E ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE;

AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; CLINICAL ARTICLE; DRIVE; DRUG EFFICACY; DRUG TOLERABILITY; EMOTION; FEMALE; HUMAN; MALE; MOTIVATION; RATING SCALE;

AFFECT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; COGNITION; FEMALE; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; OUTPATIENTS; PSYCHOMOTOR AGITATION; RETROSPECTIVE STUDIES; RISPERIDONE; TREATMENT OUTCOME;

EID: 0034480793     PISSN: 10416102     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1041610200006633     Document Type: Article

References (29)

1. The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and theoretical foundations
2. Clinical Dementia Rating scale
3. Risperidone in elderly schizophrenic patients
4. Extrapyramidal side effects in patients with Alzheimer's disease treated with low-dose neuroleptic medications
5. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
6. Neuroleptic treatment of agitation and psychosis in dementia
7. Positive and negative features in Alzheimer's disease
8. Management of the behavioral symptoms associated with dementia
9. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician
10. Methylphenidate treatment of negative symptoms in patients with dementia
11. Development of a rating scale for primary depressive illness
12. Risk of tardive dyskinesia in older patients
13. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized double-blind trial
14. Positive and Negative Syndrome Scale (PANSS) for schizophrenia
15. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease
16. The five factor model of schizophrenia: Initial validation
17. Risperidone in the treatment of schizophrenia
18. Noncognitive disturbances in Alzheimer's disease: Frequency, longitudinal course, and relationship to cognitive symptoms
19. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease
20. Metrifonate benefits cognitive, behavioral and global function in Alzheimer's disease patients
21. Risperidone in the treatment of schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol
22. Dementia and antipsychotic drugs
23. Negative symptoms in Alzheimer's disease
24. Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment
25. Aggressive behavior in persons with dementia who live in the community
26. Outcome of risperidone therapy in elderly patients with chronic psychosis
27. Drug induced extrapyramidal disorders
28. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease